Why the Ro and Eli Lilly KwikPen move matters for obesity drug access, adherence, and pricing
Ro launches Eli Lilly’s Zepbound KwikPen nationwide. Read what this means for GLP-1 access, pricing, adherence, and obesity care models.
How DarioHealth aims to strengthen oral GLP-1 effectiveness through precision behavioral health tools
DarioHealth targets oral GLP-1 therapy support with behavioral digital tools. Discover how digital health platforms could reshape obesity and diabetes treatment.